Capital International Investors
EDIT icon

Capital International Investors’s Editas Medicine EDIT Stock Holding History

Capital International Investors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-152,000
Closed -$3.46M – 384
2018
Q4 		$3.46M Hold
152,000
– – ﹤0.01% 367
2018
Q3 		$4.84M Buy
+152,000
New +$4.91M ﹤0.01% 366

Other funds holding EDIT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

Capital International Investors's EDIT Position: Q1 2019 in Review

Capital International Investors sold out of Editas Medicine (EDIT) in Q1 2019, closing a stake of 152,000 shares — an estimated $3.46M sold.

Capital International Investors first reported a position in EDIT in Q3 2018 and held it in 2 quarters. The position peaked at $4.84M in Q3 2018. 201 funds tracked by Wall St. Rank hold EDIT as of Q1 2019.

  • Capital International Investors reported no remaining Editas Medicine position as of Q1 2019 after selling out during the quarter.
  • Capital International Investors sold 152,000 Editas Medicine shares in Q1 2019, an estimated $3.46M.
  • Capital International Investors first reported a position in Editas Medicine in Q3 2018 and held it in 2 quarters.
  • Capital International Investors's Editas Medicine position peaked at $4.84M in Q3 2018.
  • 201 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2019.

Based on Capital International Investors's 13F filing for Q1 2019, filed 15 May 2019.